Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report.
Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report.
复制标题
Sintilimab治疗后具有多器官毒性的胰腺癌患者的长期生存率：病例报告。
DOI：
10.3389/fphar.2023.1121122
复制
发表时间：
2023
影响因子：
5.6
通讯作者：
Xu, Qing
中科院分区：
文献类型：
--
作者：
Ni, Chen-Xu;Zhao, Yu;Qian, Hong;Fu, Hui;Yan, Yu-Ying;Qiu, Yu-Shuang;Zhou, Can-Can;Huang, Fang;Shen, Fu-Ming;Li, Dong-Jie;Xu, Qing
胰腺癌是我国消化道恶性肿瘤中死亡的首要原因。尤其是化学疗法和靶向疗法在延长胰腺癌患者的生存期方面尚无突破。肿瘤免疫治疗为胰腺癌的治疗带来机遇和进展。信迪利单抗是一种创新的 PD-1 抑制剂，据报道在吉西他滨对晚期胰腺癌的多线治疗中具有一定的临床益处。 PD-1联合吉西他滨联合高强度聚焦超声（HIFU）治疗胰腺癌尚未见报道。这里我们报道一例被诊断出患有转移性胰腺癌的中国老年患者。信迪利单抗治疗两个月后，患者出现严重的免疫性结肠炎。治疗8个月后，患者被诊断为免疫性输尿管炎。免疫相关不良事件（irAE）经过临床医生和临床药师的及时识别和正确干预后得到细化。经过信迪利单抗加吉西他滨联合胰腺HIFU一线治疗后，患者取得了11个月无进展生存期（PFS）和20个月总生存期（OS）的显着获益。信迪利单抗联合吉西他滨联合HIFU一线治疗显示出对转移性胰腺癌的潜在治疗效果，且不良反应可耐受。
Pancreatic carcinoma is the leading cause of death among digestive malignancies in China. In particular, there is no breakthrough in prolonging the survival of pancreatic cancer patients with chemical and targeted therapies. Tumor immunotherapy brings opportunities and progress for the treatment of pancreatic cancer. Sintilimab is an innovative PD-1 inhibitor which was reported certain clinical benefits in multi-line treatments of advanced pancreatic cancer with gemcitabine. The combination therapy of PD-1 with gemcitabine plus high-intensity focused ultrasound (HIFU) in pancreatic cancer has not been reported. Here we report a case of a Chinese old patient diagnosed with metastatic pancreatic cancer. Two months after sintilimab treatment, the patient occurred severe immune colitis. The patient was diagnosed with immune ureteritis after 8 months of treatment. The immue-related adverse events (irAEs) refined after timely recognition and correct intervention by the clinician and clinical pharmacist. After first-line treatment of sintilimab plus gemcitabine combined with pancreatic HIFU, the patient achieved a remarkable benefit of 11-month progression-free survival (PFS) and 20-month overall survival (OS). The first-line treatment of sintilimab plus gemcitabine combined with HIFU demonstrates a potential therapeutic effect on metastatic pancreatic carcinoma with tolerable adverse reactions.
登录
查看更多内容
影响因子：
10.9
作者：
Sheybani, Natasha D.;Witter, Alexandra R.;Price, Richard J.
通讯作者：
Price, Richard J.
影响因子：
4.7
作者：
Guo, Honghai;Ding, Ping'an;Sun, Chenyu;Yang, Peigang;Tian, Yuan;Liu, Yang;Lowe, Scott;Bentley, Rachel;Li, Yaru;Zhang, Zhidong;Wang, Dong;Li, Yong;Zhao, Qun
通讯作者：
Zhao, Qun
影响因子：
1.1
作者：
通讯作者：
--
影响因子：
--
作者：
Mucileanu, Adrian;Chira, Romeo;Mircea, Petru Adrian
通讯作者：
Mircea, Petru Adrian
影响因子：
5.8
作者：
Abu-Sbeih, Hamzah;Ali, Faisal S.;Wang, Yinghong
通讯作者：
Wang, Yinghong